Mimetogen appoints Kim Brazzell CMO
This article was originally published in Scrip
Mimetogen Pharmaceuticals, a private company focused on developing the use of peptidomimetics as a novel approach to treating ophthalmic diseases, has appointed Dr Kim Brazzell chief medical officer. Dr Brazzell will lead the development of Mimetogen's MIM-D3 pivotal programme for the treatment of dry eye. He previously held several executive positions at Inspire Pharmaceuticals, including executive vice-president of medical and scientific affairs.